PMID- 35857060
OWN - NLM
STAT- MEDLINE
DCOM- 20220822
LR  - 20221207
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 107
IP  - 9
DP  - 2022 Aug 18
TI  - Changes in Treatment Satisfaction Over 3 Years in Patients With Type 2 Diabetes 
      After Initiating Second-line Treatment.
PG  - 2424-2432
LID - 10.1210/clinem/dgac420 [doi]
AB  - CONTEXT: J-DISCOVER is a prospective observational cohort study aiming to 
      understand the current management of patients with early-stage type 2 diabetes 
      mellitus (T2DM) in Japan, enrolling patients initiating second-line treatment. 
      OBJECTIVE: The current analysis examined the change in treatment satisfaction 
      during the study period and factors affecting this change among patients in 
      J-DISCOVER. METHODS: We used data from the J-DISCOVER study, in which 1798 
      patients with T2DM aged >/= 20 years were enrolled from 142 sites across Japan. 
      Treatment satisfaction was assessed using the Diabetes Treatment Satisfaction 
      Questionnaire (DTSQ). RESULTS: The mean DTSQ treatment satisfaction score 
      increased from 25.9 points at baseline to 27.3 points at 6 months, which was 
      maintained through 36 months. Among the baseline characteristics examined, higher 
      baseline DTSQ treatment satisfaction scores (P < 0.0001), older age (>/= 75 vs < 65 
      years, P = 0.0096), living alone (P = 0.0356), and type of facility (clinics vs 
      hospitals, P = 0.0044) had a significantly negative impact on the changes in DTSQ 
      treatment satisfaction scores. Improvement in mean glycated hemoglobin (HbA1c) 
      from baseline (7.7%) to 36 months (7.1%) was associated with positive changes in 
      the DTSQ treatment satisfaction score (P = 0.0003). CONCLUSION: Changes in DTSQ 
      treatment satisfaction scores were related to HbA1c improvement, suggesting that 
      the management strategy was appropriately planned for each patient. The results 
      also suggest that the availability of social support for patients with T2DM who 
      are elderly or living alone may be an important factor affecting treatment 
      satisfaction, adherence, and clinical outcomes.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the 
      Endocrine Society.
FAU - Mita, Tomoya
AU  - Mita T
AD  - Department of Metabolism and Endocrinology, Juntendo University Graduate School 
      of Medicine, Tokyo, Japan.
FAU - Katakami, Naoto
AU  - Katakami N
AD  - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 
      Osaka, Japan.
FAU - Takahara, Mitsuyoshi
AU  - Takahara M
AD  - Department of Diabetes Care Medicine, Graduate School of Medicine, Osaka 
      University, Osaka, Japan.
FAU - Kawashima, Masaru
AU  - Kawashima M
AD  - Ono Pharmaceutical Co., Ltd., Osaka, Japan.
FAU - Wada, Fumitaka
AU  - Wada F
AD  - AstraZeneca K.K., Osaka, Japan.
FAU - Akiyama, Hiroki
AU  - Akiyama H
AD  - AstraZeneca K.K., Osaka, Japan.
FAU - Morita, Naru
AU  - Morita N
AD  - AstraZeneca K.K., Osaka, Japan.
FAU - Kidani, Yoko
AU  - Kidani Y
AD  - AstraZeneca K.K., Osaka, Japan.
FAU - Yajima, Toshitaka
AU  - Yajima T
AUID- ORCID: 0000-0001-8409-4937
AD  - AstraZeneca K.K., Osaka, Japan.
FAU - Shimomura, Iichiro
AU  - Shimomura I
AD  - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 
      Osaka, Japan.
FAU - Watada, Hirotaka
AU  - Watada H
AUID- ORCID: 0000-0001-5961-1816
AD  - Department of Metabolism and Endocrinology, Juntendo University Graduate School 
      of Medicine, Tokyo, Japan.
LA  - eng
SI  - ClinicalTrials.gov/NCT02322762
SI  - ClinicalTrials.gov/NCT02226822
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Aged
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Patient Satisfaction
MH  - Personal Satisfaction
MH  - Prospective Studies
PMC - PMC9387712
OTO - NOTNLM
OT  - DTSQ
OT  - Diabetes Treatment Satisfaction Questionnaire
OT  - J-DISCOVER
OT  - patient-reported outcome
OT  - treatment satisfaction
OT  - type 2 diabetes mellitus
EDAT- 2022/07/21 06:00
MHDA- 2022/08/23 06:00
PMCR- 2022/07/20
CRDT- 2022/07/20 11:13
PHST- 2022/03/23 00:00 [received]
PHST- 2022/07/21 06:00 [pubmed]
PHST- 2022/08/23 06:00 [medline]
PHST- 2022/07/20 11:13 [entrez]
PHST- 2022/07/20 00:00 [pmc-release]
AID - 6647028 [pii]
AID - dgac420 [pii]
AID - 10.1210/clinem/dgac420 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2022 Aug 18;107(9):2424-2432. doi: 
      10.1210/clinem/dgac420.